Hoersholm, 2014-08-25 13:34 CEST (GLOBE NEWSWIRE) --
Company announcement no. 36/2014
On 15 January 2014 Chr. Hansen initiated a share buy-back program in compliance with the EU Commission Regulation no. 2273/2003 of 22 December 2003 (the Safe Harbor regulation). The purpose of the share buy-back program is to adjust the capital structure by distributing excess capital to the shareholders.
Under the program Chr. Hansen will buy-back shares for an amount of up to EUR 80,000,000 in the period from 15 January 2014 to 22 August 2014.
The following transactions have been made under the program in the period 18 August 2014 to 22 August 2014:
| No. of Shares | Average Price, DKK | Transaction value, EUR | |||
| 1: | 18 August 2014 | 12,958 | 228.01 | 396,057 | |
| 2: | 19 August 2014 | 10,160 | 230.27 | 313,612 | |
| 3: | 20 August 2014 | 12,500 | 230.65 | 386,485 | |
| 4: | 21 August 2014 | 15,756 | 229.58 | 484,891 | |
| 5: | 22 August 2014 | 13,787 | 230.48 | 425,953 | |
| Accumulated under the program | 2,647,480 | 79,999,985 | |||
Chr. Hansen’s accumulated share buy-backs in the period from 15 January 2014 to 22 August 2014 thus total 2,647,480 shares at a total purchase price of EUR 79,999,985. The share buy-back program has now been concluded. At Chr. Hansen’s Annual General Meeting it will be propose that the shares purchased under the share buy-back program will be cancelled.
Following the above transactions, Chr. Hansen owns a total of 3,949,400 treasury shares corresponding to 2.9% of the issued share capital.
For further information, please contact:
Anders Mohr Christensen, Senior Director, Investor Relations
Tel: +45 4574 7618
About Chr. Hansen
Chr. Hansen is a global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. The products include cultures, enzymes, probiotics and natural colors, and all solutions are based on strong research and development competencies coupled with significant technology investments. Revenue in the 2012/13 financial year was EUR 738 million. The company holds a leading market position in all its divisions: Cultures & Enzymes, Health & Nutrition and Natural Colors. It has more than 2,500 dedicated employees in 30 countries and main production facilities in Denmark, France, USA and Germany. Chr. Hansen was founded in 1874 and is listed on NASDAQ OMX Copenhagen. For further information, please visit www.chr-hansen.com .
